Here are 7 things, in no particular order, that current and prospective investors in Insys should pay attention to from its recent earnings release.
Net Revenues in Q2 of 2017 were $42.6 million, down 38% from $69.2 million, in the second quarter of 2016. The revenue decline observed in the quarter can be attributed to lower Subsys prescriptions (the company’s only commercialized product in this reporting quarter) related to soft demand for long-acting opioids more broadly.
Sales and Marketing Expenses increased to 38% of net revenues in Q2 of 2017, or $13.3 million compared to 28% of net revenue, and $19.7 million in the second quarter of last year.
Research and Development Expenses decreased to $14.1 million for Q2 of 2017 versus $22.9 million in Q2’16. This decrease in R&D expenses can be attributed to the timing of new product development costs.